Updates from Syncona and our portfolio companies
Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the appointment of Kenneth Galbraith as Executive in Residence. Ken brings over 30 years’ experience in biotechnology and venture capital and will work alongside the Syncona Investment Management Limited team to support portfolio companies as they scale and develop.
Our CIO, Chris Hollowood, discusses the future of medicine in the wake of coronavirus with Professor David Aanensen (Big Data Institute Oxford), Professor Peter Horby (Oxford University), moderated by John McConnell (The Lancet Infectious Diseases).
The Syncona Foundation today announced a donation of £301,500 over three years to charity Generating Genius, becoming their largest scholarship funder.
Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and Syncona, with participation from Polaris Partners and Pontifax. Seed investors Vida Ventures, TPG and Two River also participated in the round.